DSG3-CAART is under clinical development by Cabaletta Bio and currently in Phase I for Pemphigus Vulgaris. According to GlobalData, Phase I drugs for Pemphigus Vulgaris have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DSG3-CAART’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DSG3-CAART is under development for the treatment of mucosal pemphigus vulgaris. The drug candidate is a chimeric autoantibody receptor (CAAR-artificial receptor) T cell which displays fragments of the autoantigen Dsg3 (Desmoglein-3), the same fragments to which PV-causing antibodies and their B cells typically bind. It is administered through intravenous route.
Cabaletta Bio overview
Cabaletta Bio (Cabaletta) is a biopharmaceutical company that discovers and develops cellular therapies for B cell-mediated autoimmune diseases. Its therapeutic platform is based on the Chimeric Antigen Receptor (CAR) T cell technology that produces autologous chimeric autoantibody receptor (CAAR) T cell products designed to destroy specific autoantibody-producing B cells while sparing normal antibody-producing B cells. The company’s lead therapeutic program is used for the treatment of prototypical B cell-mediated autoimmune disease, mucosal pemphigus vulgaris (mPV) which is a rare skin disorder that causes painful blisters and sores. The company develops its products in the therapeutic areas of autoimmune disease, mucosal pemphigus vulgaris, and oncology indications. Cabaletta is headquartered in Radnor, Pennsylvania, the US.
For a complete picture of DSG3-CAART’s drug-specific PTSR and LoA scores, buy the report here.